Results 51 to 60 of about 208,148 (266)

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
A Foudi, A Gothot, A Strife, A Wilson, AHG Hamilton, AR Oller, Bayard Clarkson, BJ Druker, C Cobaleda, C Roche-Lestienne, CH Jamieson, Christophe Fraser, CL Sawyers, D Dingli, E Passegue, F Arai, F Michor, F Michor, F Michor, Franziska Michor, GB Bradford, H Glimm, HG Jorgensen, I Roeder, J Cashman, J Cortes, Jasmine Foo, JC Wang, JD Rowley, JF Apperley, KJ Hope, KW Orford, L Ponchio, M Holtz, Mark W. Drummond, ME Gorre, MJ Mauro, MW Drummond, N Uchida, NL Komarova, NL Komarova, NP Shah, P Rousselot, PS Kim, S Branford, S Branford, S Merante, SM Graham, T Higashi, T Holyoake, T Lapidot, T Reya, Tessa Holyoake, TL Holyoake, W Ghanima, WR Bruce, Y Wang   +56 more
core   +3 more sources

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors

Iraqi Journal of Hematology, 2020
BACKGROUND: Chronic myelogenous leukemia (CML) is a hematological stem cell disorder that associates with mutations in BCR-ABL. Although mutations identified in more than 30 different amino acids, the highest degree of resistance was associated with ...
Riyam Qusay Ibrahim Al-Jadir, Jaffar Nouri Alalsaidissa   +1 more
doaj   +1 more source

Allogeneic stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy [PDF]

Vojnosanitetski Pregled, 2012
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative approach, to be precise, clearly improved treatment efficacy for chronic myeloid leukemia (CML).
Stamatović Dragana, Balint Bela, Tukić Ljiljana, Elez Marija, Tarabar Olivera, Todorović Milena, Todorić-Živanović Biljana, Ostojić Gordana, Tatomirović Željka, Marjanović Slobodan, Malešević Milomir   +10 more
doaj   +1 more source

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]

, 2003
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Chen, Xiao, Guenther, Wolfgang, Kolb, Hans-Jochem, Ledderose, Georg, Roskrow, Marie, Schleuning, Michael, Schmid, Christoph, Weber, Martin, Woiciechowski, Anja   +8 more
core   +1 more source

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]

, 2016
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno, Canonico, Pier Luigi, Condorelli, Fabrizio, De Dominici, Marco, Genazzani, Armando A, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Riva, Beatrice, Salomoni, Paolo   +10 more
core   +2 more sources

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Journal of Hematology & Oncology, 2020
Background The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic ...
Xin-hua Xiao, Ping Liu, Donghe Li, Zhizhou Xia, Peihong Wang, Xiuli Zhang, Mingzhu Liu, L. Liao, B. Jiao, R. Ren   +9 more
semanticscholar   +1 more source

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice

Hematology, Transfusion and Cell Therapy, 2022
Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success.
Carla Boquimpani, Fernanda Salles Seguro, Gustavo Henrique Romani Magalhães, Ingrid Luise Soares Pinto, Israel Bendit, Jaisson André Pagnoncelli Bortolini, Katia Borgia Barbosa Pagnano, Renato Centrone, Vaneuza Funke   +8 more
doaj  

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors [PDF]

, 2014
Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR-ABL which activates a number of signal transduction pathways, including PI3K/AKT signaling and consequently inactivates FOXO transcription factors.
Bhatia, Birkenkamp, Breitling, Bruennert, Brunet, Burgering, Chomel, Chu, Copland, Corbin, Druker, Duy, Essafi, Fernandez de Mattos, Ghaffari, Goldman, Graham, Hamilton, Hurtz, Ito, Jorgensen, Kikuchi, Komatsu, Koschmieder, Mahon, Matsumoto, Miyamoto, Naka, Pellicano, Pellicano, Pellicano, Ross, Ross, Rowley, Sarbassov, Skorski, Tothova, Tothova, Trotman   +38 more
core   +2 more sources